Research programme: acute pain therapeutics - Scilex PharmaceuticalsAlternative Names: D2T patch - Scilex Pharmaceuticals
Latest Information Update: 28 Nov 2016
At a glance
- Originator Scilex Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute pain
Most Recent Events
- 04 Mar 2016 Preclinical trials in Acute pain in Europe (Topical)
- 04 Mar 2016 Preclinical trials in Acute pain in USA (Topical)